48 research outputs found
Recommended from our members
The Co-operative Alternative and the Creative Industries: A Technical Report on a Survey of Co-operatives in the cultural and technology sectors in Canada, the United Kingdom, and the United States.
This report presents the findings of a 2019 online survey of co-operatives in creative industries in Canada, the UK, and the US. This survey was an international collaboration between the SSHRC-supported project, âPathways beyond Precarity in the Cultural and Creative Industries: Sustainable Livelihoods and Cultures of Solidarity,â and the British Academy-supported project, âMapping Cultural Co-operatives.â This technical report is a companion to our community publication, Sharing Like We Mean It: Working Co-operatively in the Cultural and Tech Sectors. Whereas the latter presents select findings for workers who are new to co-ops, this technical report provides a fuller account of the results for co-op researchers, associations, policymakers, and other interested readers.
Our survey was initiated in the context of research on cultural work. Scholars have produced extensive evidence of the precarity faced by workers in creative industries, including arts and culture, media and communication, and information technology. As the perils of Big Tech and the precarity of cultural work have become increasingly contentious, the need to explore and enact worker-centered strategies for democratizing labour and sustaining livelihoods has become urgentâall the more so in the face of the ongoing COVID-19 pandemic, which has hit self-employed cultural workers particularly hard. While the co-operative model has recently begun to receive more attention among researchers seeking alternative work structures for the cultural and tech sectors, knowledge of the co-op landscape in the creative industries and the conditions of work therein remains limited. Building on Dave Boyle and Kate Oakleyâs reflections on the complementarities of co-ops and creative industries, this report summarizes findings from our 2019 survey of creative-sector co-ops in Canada, the UK, and the US.
In undertaking this survey, we set out to generate a preliminary portrait of co-op presence in creative industries; working conditions within creative-sector co-ops; the benefits of working co-operatively; reasons why cultural and tech workers choose the co-op option; and creative-sector co-opsâ involvement in the wider co-operative movement.
As further described in Sharing Like We Mean It: Working Co-operatively in the Cultural and Tech Sectors, the results of our survey confirm that the co-op model is a promising strategy for mitigating individualized patterns of work, democratizing work relationships, and providing satisfying work in creative industries contexts. While co-ops are not a magic solution to systemic work problems, our research is suggestive of co-opsâ potential to remake work in ways that have yet to be fully realized, or widely tested, in creative industries
Recommended from our members
Sharing Like We Mean It: Working Co-operatively in the Cultural and Tech Sectors.
A hybrid research report and co-op primer, Sharing Like We Mean It: Working Co-operatively in the Cultural and Tech Sectors is based on a survey of 106 co-operatives in Canada, the UK, and the US. It offers a snapshot of the co-op landscape in creative industries, explores what co-operative work can look like in practice, and features profiles of several worker co-operatives. Our survey results confirm that the co-operative model is a promising strategy for mitigating individualized patterns of work, democratizing work relationships, and providing satisfying work in creative industries contexts. Co-ops are not a magic solution to systemic work problems. But the co-op model â in conjunction with other pro-worker policies and organizations â holds potential to democratically remake work in ways that have yet to be fully realized, or widely tested, in creative industries
Properties of monocytes generated from haematopoietic CD34+ stem cells from bone marrow of colon cancer patients
Monocytes exhibit direct and indirect antitumour activities and may be potentially useful for various forms of adoptive cellular immunotherapy of cancer. However, blood is a limited source of them. This study explored whether monocytes can be obtained from bone marrow haematopoietic CD34(+) stem cells of colon cancer patients, using previously described protocol of expansion and differentiation to monocytes of cord blood-derived CD34(+) haematopoietic progenitors. Data show that in two-step cultures, the yield of cells was increased approximately 200-fold, and among these cells, up to 60Â % of CD14(+) monocytes were found. They consisted of two subpopulations: CD14(++)CD16(+) and CD14(+)CD16(â), at approximately 1:1 ratio, that differed in HLA-DR expression, being higher on the former. No differences in expression of costimulatory molecules were observed, as CD80 was not detected, while CD86 expression was comparable. These CD14(+) monocytes showed the ability to present recall antigens (PPD, Candida albicans) and neoantigens expressed on tumour cells and tumour-derived microvesicles (TMV) to autologous CD3(+) T cells isolated from the peripheral blood. Monocytes also efficiently presented the immunodominant HER-2/neu(369â377) peptide (KIFGSLAFL), resulting in the generation of specific cytotoxic CD8(+) T lymphocytes (CTL). The CD14(++)CD16(+) subset exhibited enhanced cytotoxicity, though nonsignificant, towards tumour cells in vitro. These observations indicate that generation of monocytes from CD34(+) stem cells of cancer patients is feasible. To our knowledge, it is the first demonstration of such approach that may open a way to obtain autologous monocytes for alternative forms of adaptive and adoptive cellular immunotherapy of cancer
Polymorphic variants of genes involved in homocysteine metabolism in celiac disease
Celiac disease (CD) is a polygenic chronic enteropathy conferring an increased risk for various nutrient deficiency states. Hyperhomocysteinemia is a frequent finding in CD and may be related to the development of venous thrombosis, cardiovascular disease, and stroke in untreated CD patients. Recently, a possible excess in the frequency of the MTHFR c.677C>T (rs1801133) gene variant in CD patients was reported. The purpose of this study was to determine if there exist differences in the distribution of polymorphic variants of genes involved in homocysteine/methyl group metabolism between CD patients and the general population. A set of 10 gene polymorphisms (MTHFR rs1801133, MTR rs1805087, MTHFD1 rs2236225, MTRR rs1801394, CBS 844ins68, BHMT1 rs7356530 and rs3733890, BHMT2 rs526264 and rs625879, and TCN2 rs1801198) was tested in 134 patients with CD and 160 matched healthy controls. The frequency of the MTR rs1805087 GG genotype in CD patients was lower than in controls (0.01 and 0.06, respectively), although statistical significance was not achieved (PÂ =Â 0.06). For the other analyzed polymorphisms, there was no evidence of difference in both allelic and genotypic distribution between cases and controls. The exhaustive Multifactor Dimensionality Reduction analysis revealed no combination of interactive polymorphisms predicting the incidence of CD. In contrast to the well-documented clinical observations of increased risks of vascular disease in patients with longstanding untreated CD, in our group of patients no significant association with CD was found for all tested polymorphic variants of genes involved in homocysteine metabolism. These findings should be replicated in studies with a larger sample size
Monocyte Subset Dynamics in Human Atherosclerosis Can Be Profiled with Magnetic Nano-Sensors
Monocytes are circulating macrophage and dendritic cell precursors that populate healthy and diseased tissue. In humans, monocytes consist of at least two subsets whose proportions in the blood fluctuate in response to coronary artery disease, sepsis, and viral infection. Animal studies have shown that specific shifts in the monocyte subset repertoire either exacerbate or attenuate disease, suggesting a role for monocyte subsets as biomarkers and therapeutic targets. Assays are therefore needed that can selectively and rapidly enumerate monocytes and their subsets. This study shows that two major human monocyte subsets express similar levels of the receptor for macrophage colony stimulating factor (MCSFR) but differ in their phagocytic capacity. We exploit these properties and custom-engineer magnetic nanoparticles for ex vivo sensing of monocytes and their subsets. We present a two-dimensional enumerative mathematical model that simultaneously reports number and proportion of monocyte subsets in a small volume of human blood. Using a recently described diagnostic magnetic resonance (DMR) chip with 1 ”l sample size and high throughput capabilities, we then show that application of the model accurately quantifies subset fluctuations that occur in patients with atherosclerosis
The European internet-based patient and research database for primary immunodeficiencies: results 2006-2008
Primary immunodeficiencies (PID) are rare diseases; therefore transnational studies are essential to maximize the scientific outcome and to improve diagnosis and therapy. In order to estimate the prevalence of PID in Europe as well as to establish and evaluate harmonized guidelines for the diagnosis and treatment of PID, the European Society for Immunodeficiencies (ESID) has developed an internet-based database for clinical and research data on patients with PID. This database is a platform for epidemiological analyses as well as the development of new diagnostic and therapeutic strategies and the identification of novel disease-associated genes. Within 4 years, 7430 patients from 39 countries have been documented in the ESID database. Common variable immunodeficiency (CVID) represents the most common entity, with 1540 patients or 20.7% of all entries, followed by isolated immunoglobulin (Ig)G subclass deficiency (546 patients, 7.4%). Evaluations show that the average life expectancy for PID patients varies from 1 to 49 years (median), depending on the type of PID. The prevalence and incidence of PID remains a key question to be answered. As the registration progress is far from finished we can only calculate minimum values for PID, with e.g. France currently showing a minimum prevalence of 3.72 patients per 100,000 inhabitants. The most frequently documented permanent treatment is immunoglobulin replacement; 2819 patients (42% of all patients alive) currently receive this form of treatment
Controlo quĂmico de infestantes
Uma planta Ă© considerada infestante quando nasce espontaneamente num local e momento indesejados, podendo interferir negativamente com a cultura instalada.
As infestantes competem com as culturas para o espaço, a luz, ågua e nutrientes, podendo atrasar e prejudicar as operaçÔes de colheita, depreciar o produto final e assegurarem a reinfestação nas culturas seguintes.
Dado o modo de propagação diferenciado das diversas espĂ©cies de infestantes, com as anuais a propagarem-se por semente e as perenes ou vivazes a assegurarem a sua propagação atravĂ©s de ĂłrgĂŁos vegetativos (rizomas, bolbos, tubĂ©rculos, etc.), assim, tambĂ©m o seu controlo quer quĂmico, quer mecĂąnico terĂĄ que ser diferenciado, ou seja, para controlar infestantes anuais serĂĄ suficiente destruir a sua parte aĂ©rea, enquanto para controlar infestantes perenes teremos que destruir os seus ĂłrgĂŁos reprodutivos.
O controlo de infestantes poderĂĄ ser quĂmico, atravĂ©s da utilização de herbicidas, ou mecĂąnico pela utilização de alfaias agrĂcolas, tais como a charrua de aivecas, a charrua de discos, a grade de discos, o escarificador e a fresa. Quando a tĂ©cnica utilizada na instalação das culturas Ă© a sementeira directa, o controlo das infestantes terĂĄ que ser obrigatoriamente quĂmico, enquanto se o recurso Ă mobilização do solo for a tĂ©cnica mais utilizada (sistema de mobilização tradicional ou sistema de mobilização reduzida), o controlo das infestantes tanto poderĂĄ ser quĂmico como mecĂąnico.
Neste trabalho iremos abordar apenas, o controlo quĂmico de infestantes
Tuberculosis is associated with expansion of a motile, permissive and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis
The human CD14+ monocyte compartment is composed by two subsets based on CD16 expression. We previously reported that this compartment is perturbed in tuberculosis (TB) patients, as reflected by the expansion of CD16+ monocytes along with disease severity. Whether this unbalance is beneficial or detrimental to host defense remains to be elucidated. Here in the context of active TB, we demonstrate that human monocytes are predisposed to differentiate towards an anti-inflammatory (M2-like) macrophage activation program characterized by theCD16+CD163+MerTK+pSTAT3+ phenotype and functional properties such as enhanced protease-dependent motility, pathogen permissivity and immunomodulation. This process is dependent on STAT3 activation, and loss-of-function experiments point towards a detrimental role in host defense against TB. Importantly, we provide a critical correlation between the abundance of the CD16+CD163+MerTK+pSTAT3+ cells and the progression of the disease either at the local level in a non-human primate tuberculous granuloma context, or at the systemic level through the detection of the soluble form of CD163 in human sera. Collectively, this study argues for the pathogenic role of the CD16+CD163+MerTK+pSTAT3+ monocyte-to-macrophage differentiation program and its potential as a target for TB therapy,and promotes the detection of circulating CD163 as a potential biomarker for disease progression and monitoringof treatment efficacy.Fil: Lastrucci, Claire. Centre National de la Recherche Scientifique; FranciaFil: BĂ©nard, Alan. Centre National de la Recherche Scientifique; FranciaFil: Balboa, Luciana. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Pingris, Karine. Centre National de la Recherche Scientifique; FranciaFil: Souriant, Shanti. Centre National de la Recherche Scientifique; FranciaFil: Poincloux, Renaud. Centre National de la Recherche Scientifique; FranciaFil: Al Saati, Talal. Inserm; FranciaFil: Rasolofo, Voahangy. Pasteur Institute in Antananarivo; MadagascarFil: GonzĂĄlez Montaner, Pablo. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas ; ArgentinaFil: Inwentarz, Sandra. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas ; ArgentinaFil: Moraña, Eduardo JosĂ©. Gobierno de la Ciudad de Buenos Aires. Hospital de Infecciosas ; ArgentinaFil: Kondova, Ivanela. Biomedical Primate Research Centre; PaĂses BajosFil: Verreck, Franck A. W.. Biomedical Primate Research Centre; PaĂses BajosFil: Sasiain, MarĂa del Carmen. Consejo Nacional de Investigaciones CientĂficas y TĂ©cnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; ArgentinaFil: Neyrolles, Olivier. Centre National de la Recherche Scientifique; FranciaFil: Maridonneau Parini, Isabel. Centre National de la Recherche Scientifique; FranciaFil: Lugo Villarino, Geanncarlo. Centre National de la Recherche Scientifique; FranciaFil: Cougoule, Celine. Centre National de la Recherche Scientifique; Franci